Melanomas News and Research RSS Feed - Melanomas News and Research

Presence of collagen in tumor microenvironment can be either good or bad

Presence of collagen in tumor microenvironment can be either good or bad

The presence of collagen in the tumor microenvironment, essentially where the tumor lives, can be either good or bad according to Constance Brinckerhoff, PhD who led the Dartmouth team's reporting of "The BRAFV600E inhibitor, PLX4032, increases type 1 collagen synthesis in melanoma cells," in Matrix Biology Journal. [More]
Skin Cancer Awareness Recommended For HCT Recipients

Skin Cancer Awareness Recommended For HCT Recipients

Patients who undergo haematopoietic cell transplantation should be educated on the risk of skin cancer and the need for regular self-examination, US researchers say. [More]
New study examines best practices in teaching medical students to better detect skin lesions

New study examines best practices in teaching medical students to better detect skin lesions

Each year, thousands of Canadians are given the news: they have skin cancer. It is the most common form of cancer in Canada and around the world, but if detected early, survival rates are extremely high. According to Liam Rourke, it doesn't happen nearly as often as it could. [More]
Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Study: Disrupting cancer pathway could extend benefits of new immunity-boosting drugs

Understanding how to overrule a signaling pathway that can cause treatments to fail in metastatic melanoma patients should help physicians extend the benefits of recently approved immunity-boosting drugs known as checkpoint inhibitors to more patients. [More]
First patient receives new 'resistance-busting' experimental skin cancer drug

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types. [More]
Scientists identify possible new genes that could change benign skin growths into fatal melanomas

Scientists identify possible new genes that could change benign skin growths into fatal melanomas

A Houston Methodist-led team of international scientists has identified hundreds of possible new genes in mice that could transform benign skin growths into deadly melanomas. [More]
New research links megalin protein with malignant melanomas

New research links megalin protein with malignant melanomas

Today it is not possible to predict spreading from malignant melanomas. Melanoma metastases are furthermore extremely difficult to eliminate as traditional treatment such as chemotherapy and radiotherapy is mostly ineffective. Only ten per cent of the patients survive once they reach an advanced stage with distant metastases. [More]
Subpopulation of tumor cells make melanoma aggressive

Subpopulation of tumor cells make melanoma aggressive

KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures. [More]
People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

Researchers from the UNC Lineberger Comprehensive Cancer Center analyzed hundreds of melanoma samples to find out if two genetic mutations more commonly found in melanoma tumors were associated with lower survival rates in patients. [More]
UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status. [More]
CXCR3 molecule is key mediator of melanoma metastasis, shows research

CXCR3 molecule is key mediator of melanoma metastasis, shows research

In a unique partnership demonstrating excellence in "team science," Dartmouth investigators from Norris Cotton Cancer Center identified a role for the molecule CXCR3 (widely known to regulate the migration of immune cells) as a key mediator of melanoma metastasis. [More]
Personalized cancer vaccines can be used to marshal powerful immune response

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. [More]
Discovery may lead to new potential treatment for drug-resistant melanoma

Discovery may lead to new potential treatment for drug-resistant melanoma

In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments. [More]
Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States. [More]
Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya's IRay Radiotherapy system gets CE Mark to treat choroidal metastases

Oraya Therapeutics announced today that the Oraya IRay® Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from primary sites in the breast or lung. [More]
Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

Pediatric Cancer Genome Project identifies genetic basis of three pediatric melanoma subtypes

The St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project found that melanoma in some adolescent and adult patients involves many of the same genetic alterations and would likely respond to the same therapy. [More]
MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein's power to spur cancer cell growth. [More]
Moffitt physicians promote novel screening strategies to decrease melanoma mortality

Moffitt physicians promote novel screening strategies to decrease melanoma mortality

Melanoma, the most deadly type of skin cancer, was to blame for approximately 9,700 deaths in 2014. And with the number of melanoma cases increasing each year, it is believed that the disease could become one of the most common types of cancer in the United States by 2030. Promoting and developing national screening strategies may help to reduce deaths due to melanoma. [More]
A*STAR's GIS scientists develop new system that can predict treatment targets for cancer

A*STAR's GIS scientists develop new system that can predict treatment targets for cancer

In recent months, several national initiatives for personalized medicine have been announced, including the recently launched precision medicine initiative in the US, driven by rapid advances in genomic technologies and with the promise of cheaper and better healthcare. Significant challenges remain, however, in the management and analysis of genetic information and their integration with patient data. [More]

New app for clinical detection of skin cancer launched on World Cancer Day

On World Cancer Day 2015, general practitioners, physicians and dermatologists in the United States, United Kingdom and Australia are being asked for their feedback during the advanced trial phase of a new, free app that has the potential to play a vital role in the clinical detection of skin cancer. [More]
Advertisement
Advertisement